CSLLY
Price
$79.76
Change
-$0.01 (-0.01%)
Updated
May 30 closing price
Capitalization
76.83B
FOLD
Price
$6.07
Change
-$0.14 (-2.25%)
Updated
May 30 closing price
Capitalization
1.87B
60 days until earnings call
Interact to see
Advertisement

CSLLY vs FOLD

Header iconCSLLY vs FOLD Comparison
Open Charts CSLLY vs FOLDBanner chart's image
CSL
Price$79.76
Change-$0.01 (-0.01%)
Volume$59.72K
Capitalization76.83B
Amicus Therapeutics
Price$6.07
Change-$0.14 (-2.25%)
Volume$3.29M
Capitalization1.87B
CSLLY vs FOLD Comparison Chart
Loading...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSLLY vs. FOLD commentary
Jun 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSLLY is a Hold and FOLD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 01, 2025
Stock price -- (CSLLY: $79.76 vs. FOLD: $6.07)
Brand notoriety: CSLLY and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSLLY: 61% vs. FOLD: 70%
Market capitalization -- CSLLY: $76.83B vs. FOLD: $1.87B
CSLLY [@Biotechnology] is valued at $76.83B. FOLD’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $303.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSLLY’s FA Score shows that 1 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • CSLLY’s FA Score: 1 green, 4 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, CSLLY is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSLLY’s TA Score shows that 6 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • CSLLY’s TA Score: 6 bullish, 4 bearish.
  • FOLD’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CSLLY is a better buy in the short-term than FOLD.

Price Growth

CSLLY (@Biotechnology) experienced а +0.01% price change this week, while FOLD (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSLLY($76.8B) has a higher market cap than FOLD($1.87B). CSLLY YTD gains are higher at: -8.156 vs. FOLD (-35.563). CSLLY has higher annual earnings (EBITDA): 4.73B vs. FOLD (53.6M). CSLLY has more cash in the bank: 1.52B vs. FOLD (251M). FOLD has less debt than CSLLY: FOLD (443M) vs CSLLY (12B). CSLLY has higher revenues than FOLD: CSLLY (14.7B) vs FOLD (543M).
CSLLYFOLDCSLLY / FOLD
Capitalization76.8B1.87B4,116%
EBITDA4.73B53.6M8,830%
Gain YTD-8.156-35.56323%
P/E Ratio29.27N/A-
Revenue14.7B543M2,707%
Total Cash1.52B251M607%
Total Debt12B443M2,709%
FUNDAMENTALS RATINGS
CSLLY vs FOLD: Fundamental Ratings
CSLLY
FOLD
OUTLOOK RATING
1..100
5052
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5392
PRICE GROWTH RATING
1..100
7491
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CSLLY's Valuation (2) in the null industry is somewhat better than the same rating for FOLD (65) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than FOLD’s over the last 12 months.

CSLLY's Profit vs Risk Rating (100) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to FOLD’s over the last 12 months.

CSLLY's SMR Rating (53) in the null industry is somewhat better than the same rating for FOLD (92) in the Biotechnology industry. This means that CSLLY’s stock grew somewhat faster than FOLD’s over the last 12 months.

CSLLY's Price Growth Rating (74) in the null industry is in the same range as FOLD (91) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to FOLD’s over the last 12 months.

CSLLY's P/E Growth Rating (75) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CSLLY’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSLLYFOLD
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
52%
Bullish Trend 16 days ago
69%
Declines
ODDS (%)
Bearish Trend 11 days ago
64%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
38%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
47%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFPUX20.590.10
+0.49%
Independent Franchise Partners US Equity
TSGDX15.500.03
+0.19%
Transamerica Sustainable Growth Eq A
RCEYX57.510.03
+0.05%
Victory RS Large Cap Alpha Y
VYMVX17.42-0.05
-0.29%
Voya Mid Cap Research Enhanced Index R
VSOIX42.89-0.27
-0.63%
Victory Sycamore Small Company Opp I

CSLLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, CSLLY has been loosely correlated with ADPT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CSLLY jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSLLY
1D Price
Change %
CSLLY100%
-0.01%
ADPT - CSLLY
34%
Loosely correlated
+2.26%
RXRX - CSLLY
34%
Loosely correlated
-6.07%
VIR - CSLLY
33%
Poorly correlated
-4.82%
FOLD - CSLLY
33%
Poorly correlated
-2.25%
CDXS - CSLLY
33%
Poorly correlated
-2.13%
More

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-2.25%
VCYT - FOLD
43%
Loosely correlated
-1.30%
ROIV - FOLD
42%
Loosely correlated
-2.74%
RARE - FOLD
41%
Loosely correlated
-2.85%
ATXS - FOLD
41%
Loosely correlated
-3.84%
KRYS - FOLD
40%
Loosely correlated
+0.28%
More